Loading asset research
Krystal Biotech Inc. Common Stock
KRYSNasdaq · USD · StocksQuote as of · Exchange session not verified$346.79
+0.36%
Today
KRYS
Loading 1D prices…
Market cap
$10.3B
Volume
206.3K
52w high
$382.5452w low
$145.46Company profile
Krystal Biotech Inc. Common Stock
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Sector
Health Care
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq
Display currency
USD
Location
Pittsburgh, PA, United States
Employees
295
Fiscal year end
1231
CIK
1711279
Session & valuation
Open$349.59
Previous close$345.55
Day high$354.24
Day low$346.68
30-day avg. volume266.8K
Outstanding shares29.6M
Diluted EPS$6.84
Latest annual period
P/E (trailing)43.32
P/E (forward)36.92
Price / book7.56
Beta0.54
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2836
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| KYMRKymera Therapeutics Inc. Common Stock | $9.5B | $39.2M | +794.04% | -$3.69 | -1.68% | Buy |
| TECHBio-Techne Corp Common Stock | $11.3B | $1.2B | +14.97% | $1.16 | +0.06% | Hold |
| RGENRepligen Corporation Common Stock | $9.3B | $738.3M | +6.62% | $0.86 | +0.29% | Buy |
| PCVXVaxcyte Inc. Common Stock | $8.8B | $0.00 | — | -$5.63 | +0.90% | Buy |
| QGENQiagen N.V. Common Shares | $8.8B | $2.1B | +20.33% | $1.94 | +0.83% | Hold |